{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:17:23Z","timestamp":1789165043911,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hellenic Journal of Cardiology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.hjc.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T08:04:43Z","timestamp":1737965083000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Sacubitril\/valsartan role in patients with resistant hypertension: a systematic review"],"prefix":"10.1016","volume":"90","author":[{"given":"Hanselim","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6594-8782","authenticated-orcid":false,"given":"Hendry","family":"Agustian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3712-2805","authenticated-orcid":false,"given":"Vanny","family":"Febriana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Inda","family":"Supit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10226","key":"10.1016\/j.hjc.2025.01.004_bib1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(19)32008-2","article-title":"Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study","volume":"395","author":"Yusuf","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.hjc.2025.01.004_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","article-title":"Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients","volume":"105","author":"Noubiap","year":"2019","journal-title":"Heart"},{"issue":"33","key":"10.1016\/j.hjc.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of Cardiology (ESC) and the European society of hypertension (ESH)","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.hjc.2025.01.004_bib4","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.hjc.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/hr.2013.30","article-title":"Resistant hypertension and target organ damage","volume":"36","author":"Muiesan","year":"2013","journal-title":"Hypertens Res"},{"issue":"11","key":"10.1016\/j.hjc.2025.01.004_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"9851","key":"10.1016\/j.hjc.2025.01.004_bib7","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hjc.2025.01.004_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.1099043","article-title":"Clinical observation of sacubitril valsartan sodium in the treatment of resistant hypertension: a randomized clinical trial","volume":"9","author":"Lyu","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.hjc.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jch.14454","article-title":"Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension","volume":"24","author":"Li","year":"2022","journal-title":"J Clin Hypertens"},{"issue":"3","key":"10.1016\/j.hjc.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/jch.14422","article-title":"Effects of Sacubitril\/Valsartan on resistant hypertension and myocardial work in hemodialysis patients","volume":"24","author":"Wang","year":"2022","journal-title":"J Clin Hypertens"},{"issue":"36","key":"10.1016\/j.hjc.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"issue":"9722","key":"10.1016\/j.hjc.2025.01.004_bib12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hjc.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","article-title":"Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study","volume":"45","author":"Rakugi","year":"2022","journal-title":"Hypertens Res"},{"issue":"6","key":"10.1016\/j.hjc.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FJC.0000000000000485","article-title":"Efficacy and safety of crystalline valsartan\/sacubitril (LCZ696) compared with placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study","volume":"69","author":"Izzo","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.hjc.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.hjc.2025.01.004_bib16","article-title":"Options for patients with out-of-control blood pressure: after all avenues have been exhausted","author":"Zeng","year":"2024229459","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"2","key":"10.1016\/j.hjc.2025.01.004_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1042\/CS20150469","article-title":"The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment","volume":"130","author":"Volpe","year":"2016","journal-title":"Clin Sci"},{"issue":"6","key":"10.1016\/j.hjc.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40292-021-00489-z","article-title":"Targeting cyclic guanylate monophosphate in resistant hypertension and heart failure: are sacubitril\/valsartan and vericiguat synergistic and effective in both conditions?","volume":"28","author":"Gallo","year":"2021","journal-title":"High Blood Pres Cardiovasc Prev"},{"issue":"30","key":"10.1016\/j.hjc.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehv142","article-title":"Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials","volume":"36","author":"Bavishi","year":"2015","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.hjc.2025.01.004_bib20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/HJH.0000000000003430","article-title":"Effect of sacubitril\/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension","volume":"41","author":"Chen","year":"2023","journal-title":"J Hypertens"},{"issue":"44","key":"10.1016\/j.hjc.2025.01.004_bib21","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.hjc.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/jch.13153","article-title":"Efficacy and safety of sacubitril\/valsartan in patients with essential hypertension uncontrolled by olmesartan: a randomized, double-blind, 8-week study","volume":"20","author":"Cheung","year":"2018","journal-title":"J Clin Hypertens"}],"container-title":["Hellenic Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966625000041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1109966625000041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T21:47:00Z","timestamp":1789163220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1109966625000041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":22,"alternative-id":["S1109966625000041"],"URL":"https:\/\/doi.org\/10.1016\/j.hjc.2025.01.004","relation":{},"ISSN":["1109-9666"],"issn-type":[{"value":"1109-9666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacubitril\/valsartan role in patients with resistant hypertension: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Hellenic Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hjc.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Hellenic Society of Cardiology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}